Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer’s Disease (AD) Date / Time: December 1, 2022 / 4:30pm PT Presenter: A/Prof. Stephen Macfarlane, Principal Investigator Session Title: LB8 - LATE BREAKING ORAL COMMUNICATIONS